Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with non–small cell lung cancer (NSCLC), as well as the optimal treatment course for patients with stage III, EGFR-mutated disease.